Connecticut State Services Portal - Recent Governor Press Releases

Connecticut's official state services portal at portal.ct.gov serves as a central hub for accessing executive, judicial, and legislative resources, including links to state employment services, tax filing, judicial case lookup, and emergency management resources. Recent news includes Governor Lamont's announcements: $1.55 million in state grants for 12 entities to increase access to locally grown food, $15 million in funding for clean air projects, and submission of the SEBAC agreement to the General Assembly. The portal also features home heating assistance programs, CT Prepares emergency management resources, and information on Connecticut's 142 state parks.

CT Dept Consumer Protection Latest News April 14

The Connecticut Department of Consumer Protection published its latest news index page on April 14, 2026, listing recent agency announcements including new guidance for pharmacists on the 2025-2026 seasonal COVID-19 vaccine, updates on controlled substance regulation changes, a summary suspension issued for White Rabbit in Hartford, and consumer alerts. The page serves as a navigation hub for agency news, division information, and resources for both consumers and businesses.

Federal District Court Denies Untimely Jurisdiction Challenge in Generic Drug Price-Fixing Case

U.S. District Judge Michael P. Shea denied Mallinckrodt PLC's motion to dismiss an antitrust action for lack of personal jurisdiction or improper service, finding the company forfeited those defenses by waiting more than five and a half years after the complaint and by actively litigating on the merits in the interim. The action by 45 state attorneys general, alleging single drug conspiracies and an overarching agreement across roughly 80 generic dermatology drugs to allocate market share, coordinate price increases, and refrain from customer poaching, will continue in Connecticut et al. v. Sandoz, Inc., No. 3:20 cv 00802 MPS (D. Conn.). The practical implications are immediate—plaintiffs may continue to pursue claims against Mallinckrodt in the Dermatology Action. For defense teams, the ruling underscores the need to preserve personal jurisdiction and service objections at the outset and to avoid conduct that courts may view as submission to jurisdiction.

FDA FY27 Budget: $7.2B, MAHA Priorities

Akin Gump analysts published a detailed breakdown of FDA's Fiscal Year 2027 budget request on April 23, 2026. The White House proposes $7.2 billion for FDA ($232M above FY26, a 3.3% increase), including $3.3B in discretionary funding and $3.9B in user fees, with a new $71M user fee for food facilities and importers. The budget outlines 27 legislative proposals addressing drug advertising, supply-chain integrity, and process modernization, while noting PDUFA/MDUFA/GDUFA/BsUFA reauthorizations are due September 30, 2027.

Canada Federal Court: Pharma Patent Venue Expertise

This JD Supra article from Bennett Jones LLP analyzes Canada's Federal Court as a preferred venue for pharmaceutical patent litigation. The Federal Court has country-wide jurisdiction and established specialized Intellectual Property and Competition Chambers in 2023 with judges experienced in pharmaceutical patent disputes. Cases brought under the Patented Medicines (Notice of Compliance) Regulations benefit from streamlined procedures including case management, early disclosure obligations, confidentiality safeguards via Protective Orders, and decisions typically issued within 24 months. Key 2026 developments include the Supreme Court of Canada's pending decision on patentable subject matter in Pharmascience v Janssen Inc, anticipated changes to anticipation doctrine, and evolving overbreadth doctrine.

FDA Exclusivities, PTA, PTE, and ODP Shape Pharmaceutical Lifecycle Value

Sterne Kessler Directors Deborah Sterling, John Covert, and Dennies Varughese presented a webinar summarizing five practical insights for pharmaceutical lifecycle strategy. The article covers how FDA regulatory exclusivities, patent term adjustment (PTA), patent term extension (PTE), and obviousness-type double patenting (ODP) interact to affect competitive entry timing. Key points include regulatory exclusivity operating as a standalone barrier, PTA introducing double patenting risk when disproportionate across related patents, and the importance of holistic planning across regulatory, prosecution, and enforcement teams to preserve product value through loss of exclusivity.

Judge Vacates Kennedy Declaration on Gender-Affirming Care for Minors

Judge Mustafa Kasubhai of the United States District Court for the District of Oregon issued an April 18, 2026 order granting summary judgment to 19 states and the District of Columbia, vacating the Kennedy Declaration in its entirety and issuing a permanent injunction against its enforcement. The court found the declaration violated the Administrative Procedure Act and Medicare Act by creating binding standards of care without notice-and-comment rulemaking, exceeded HHS statutory authority by superseding professionally recognized medical standards, and conflicted with federally approved state Medicaid plans covering gender-affirming care.

Trump Administration Advances Psychedelics via Executive Order

President Trump signed an executive order in April 2026 directing federal agencies to study ibogaine as a treatment for PTSD, traumatic brain injury, and opioid dependence in veterans, with HHS Secretary RFK publicly expressing urgency to expand psychedelic therapy access. The order directs FDA and DEA to establish a Right to Try pathway for eligible patients to access investigational psychedelics including psilocybin and ibogaine, and allocates at least $50 million in existing HHS funds to support state programs advancing psychedelic drugs for serious mental illness. Once a Schedule I substance completes Phase 3 trials for a serious mental health disorder, the attorney general is directed to initiate rescheduling review under 21 U.S.C. § 811.

Significance of Proposed CJR-X National Joint Replacement Payment Model for Hospitals

CMS published the FY2027 IPPS proposed rule on April 10, 2026, proposing the Comprehensive Care for Joint Replacement Expansion (CJR-X) model, which would be the first CMS Innovation Center expanded model under this administration. The proposed mandatory national model would cover Medicare fee-for-service beneficiaries undergoing lower-extremity joint replacement (MS-DRGs 469, 470, 521, 522 for inpatient; HCPCS 27130 and 27447 for outpatient), with 90-day post-discharge episodes beginning October 1, 2027. The model draws on the original CJR model's evidence of $112.7 million in net savings across performance years six and seven while maintaining quality of care, satisfying the statutory expansion criteria under Section 1115A of the Social Security Act.

Healthcare M&A Analysis Q1 2026 Steady Activity

Q1 2026 saw steady healthcare M&A activity across physician practice management, clinical research, hospitals, and digital health, with key deals including Cencora's ~$4.6 billion acquisition of OneOncology and its $1.1 billion agreement to acquire EyeSouth Partners' retina business. A wave of state legislation in Connecticut, Rhode Island, and Minnesota targets PE-backed physician practice and MSO transactions, with bills proposing certificate-of-need expansions, corporate practice of medicine codification, and restrictions on MSO arrangements with physician practices. GE HealthCare's $2.3 billion acquisition of Intelerad underscores AI's emergence as foundational healthcare infrastructure.

Skinny Label Patent Inducement: SCOTUS to Review Hikma v. Amarin

The United States Supreme Court granted certiorari on January 16, 2026, in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (No. 24-889), agreeing to decide the scope of induced patent infringement liability when generic manufacturers use the FDA's skinny-label pathway. The Federal Circuit reversed the District Court for the District of Delaware, reviving Amarin's claims that Hikma's external marketing communications (press releases, investor materials, website listings) induced physicians to prescribe the generic for a patented cardiovascular indication despite Hikma's compliant Section viii carve-out in its ANDA label. Oral argument is scheduled for April 29, 2026, with a decision expected before the Court's summer recess.

House Ways and Means Hears Testimony on Hospice, Home Health Fraud

The House Ways and Means Committee held a hearing on April 21, 2026 titled 'Protecting Patients and Taxpayers: Cracking down on Medicare Fraud' at which Sheila Clark, President and CEO of the California Hospice and Palliative Care Association, and Chris Deery, Director of Corporate Fraud & Investigations for Independence Blue Cross, provided testimony. Both witnesses described organized, sophisticated fraud schemes targeting Medicare hospice and home health programs that exploit vulnerable beneficiaries through uninformed consent, stolen identities, and payments for Medicare numbers. The witnesses identified specific warning signs of fraudulent providers and proposed policy recommendations including strengthened front-end screening, earlier use of enforcement remedies, and improved analytics to detect fraud at the beneficiary level.

Federal Circuit Revives Gene-Therapy Patent Under Section 101

In February 2026, the U.S. Court of Appeals for the Federal Circuit reversed a District of Delaware summary judgment in REGENXBIO Inc. v. Sarepta Therapeutics, Inc., reinstating patent eligibility for U.S. Patent No. 10,526,617 covering genetically engineered host cells with recombinant adeno-associated virus (AAV) sequences. The three-judge panel unanimously held that the recombinant, heterologous molecules—which combine genetic sequences from multiple organisms through human intervention—possess 'markedly different characteristics' from any natural product and therefore constitute patent-eligible subject matter under Section 101. The decision aligns with the Supreme Court's Diamond v. Chakrabarty framework and provides guidance on distinguishing engineered biologics from products of nature.

Former Southeast Greene Water Authority Office Manager Arrested for $25k Embezzlement

State Auditor Shad White announced that Special Agents from the Mississippi State Auditor's Office have arrested Deborah Harper, former Southeast Greene Water Authority office manager, for allegedly embezzling $25,000 in funds belonging to the water authority. Harper allegedly received cash payments from new customer water agreement forms and converted the funds for her own personal use. Additionally, Harper allegedly utilized water user payments from other account holders to satisfy water debt for both herself and her daughter. If convicted, Harper faces up to $25,000 in fines and up to 10 years in prison.

Mississippi Auditor Demands MTC Repay $7.4M

State Auditor Shad White issued over $7.4 million in civil demands to Management & Training Corporation (MTC) for improper staffing credits at three Mississippi correctional facilities: $462,299.32 for East Mississippi Correctional Facility, $959,240.06 for Marshall County Correctional Facility, and $6,002,027.92 for Wilkinson County Correctional Facility. The demands have been referred to the Attorney General's Office for enforcement in court. The investigation found that MTC was paid as if it had provided required minimum staffing but failed to actually provide those staff at the contracted facilities.

Three Arrests in Operation Payback Unemployment Fraud

State Auditor Shad White announced the arrest of Chadwick Stubbs, Blair Stubbs, and Shinka Stubbs on April 21, 2026, as part of Operation Payback, an investigation into unemployment compensation fraud. The three individuals allegedly submitted fraudulent unemployment claims using the identities of thirteen inmates who were incarcerated with Blair and Chadwick Stubbs at the time the claims were filed with the Mississippi Department of Employment Security. If convicted, the Stubbs face up to $36,000 in fines and up to 45 years in prison. State Auditor White noted that Mississippi distributed over half a billion dollars in improper unemployment payments during the COVID-19 pandemic.

Stability Testing Medicated Premix Draft Guidance Revision 1

FDA's Center for Veterinary Medicine has published a draft revision (Revision 1) of guidance CVM GFI #91 (VICH GL8(R)), providing updated recommendations for stability testing of Medicated Premix products intended for EU, Japan, and US registration applications. This guidance serves as an annex to the parent guidance VICH GL3 and addresses stability considerations specific to drug products incorporated into animal feed. The comment period closes on June 15, 2026.

Agencies Finalize 8% Community Bank Leverage Ratio Rule

The FDIC, Federal Reserve Board, and Office of the Comptroller of the Currency jointly finalized amendments to the Community Bank Leverage Ratio Framework, lowering the required ratio from nine percent to eight percent and extending the grace period for temporary non-compliance from two quarters to four quarters. The rule, adopted without change from the November 2025 proposal, takes effect on July 1, 2026 and is designed to provide community banks with greater flexibility and reduced regulatory burden while maintaining safety and soundness requirements.

Addison County Job Center Reduces Hours Starting March 30

The Vermont Department of Labor announces that effective Monday, March 30, 2026, the Middlebury Job Center location will operate on reduced hours. The new location is 156 S. Village Green (HireAbility Suite), open Monday and Tuesday from 9:00 AM to 3:30 PM, with walk-ins welcome. Services will continue in Addison County with expanded staff capacity through Rutland office support.

Non-Piezoelectric Flexible Resonator Promotes Cell Division, Migration

Application US20260109964A1 was filed on August 28, 2025 by inventors Won-gun KOH, Hyungsuk LEE, Donyoung KANG, Byeongseok RYU, Sujeong AHN, and Chanryeol RHYOU, and published on April 23, 2026. The application covers a resonator that promotes cell division and migration using an interdigitated electrode structure deposited on a dielectric polymer substrate surface, generating acoustic waves when alternating current at resonant frequency is applied. The technology is classified under CPC codes C12N 13/00 and C12M 35/04. While the application does not yet grant enforceable rights, it establishes a priority date for the claimed non-piezoelectric flexible resonator technology in the biomedical device space.

Patent Application for Adipocyte Cytotoxic Protein Constructs for Fat Reduction

Matthew Rein Scholz and Gary Charles Hudson filed US Patent Application 19281400 on July 25, 2025, published April 23, 2026, covering polynucleotide constructs that enable adipocyte-specific production of cytotoxic proteins for reducing adipose tissue volume in visceral, subcutaneous, and abdominal fat deposits. The application also discloses lipid-based delivery vectors for administering these constructs. This is a patent application publication (Kind A1), not a granted patent, and does not yet confer any exclusive rights or compliance obligations on third parties.

Methods of Treating Pulmonary Sarcoidosis With DNA Nucleases

USPTO published patent application US20260109959A1 on April 23, 2026, disclosing methods for treating pulmonary sarcoidosis via inhalation of human recombinant DNase1 or other DNA nucleases. The application, filed January 18, 2025, names inventors Brian William Davies, Daniel S. Cartwright, and Ira Kalfus. The invention proposes that DNA nucleases reduce excessive lung DNA that stimulates TLR9 receptors, thereby decreasing inflammation, cytokine release, and granuloma formation characteristic of sarcoidosis.

Nucleic Acid Purification Using Mixed Mode Resins

USPTO published patent application US20260109965A1 titled 'Purification of Nucleotides by Means of a Mixed-Mode Purification System,' filed September 27, 2023 (Application No. 19115842). The invention relates to purification of nucleotides using mixed mode resins and names four inventors: Jennifer Beaudoin, Matthew J. Burak, Christopher Ladd Effio, and Haripriya Sharma. CPC classifications include C12N 15/101, B01J 20/262, and C12N 15/1017.

Novozymes A/S Alpha-Amylase Enzyme Variants and Polynucleotides Patent Application

Novozymes A/S has filed US Patent Application US20260109960A1 (Application No. 19363135) titled 'ENZYME VARIANTS AND POLYNUCLEOTIDES ENCODING THE SAME', published April 23, 2026, with a filing date of October 20, 2025. The application covers polypeptides with alpha-amylase activity, encoding polynucleotides, nucleic acid constructs, vectors, host cells, and associated production methods. CPC classifications include C12N 9/2414, C11D 3/386, and related biotechnological categories indicating commercial applications in cleaning products and industrial enzyme production. Eight named inventors are listed, including Torsten Bak Regueira, Bitten Plesner, Thomas Holberg Blicher, Anne Dorte Houg, Sofia Arnehed, Lars Lehmann Hylling Christensen, and Carsteen Andersen.

Recombinant Endopeptidase Production Method

NEMYSIS LIMITED filed US Patent Application US20260109962A1 on July 2, 2025, covering a method for manufacturing an enzyme preparation comprising recombinant Actinoallomurus endopeptidase with glutenase activity at high yields suitable for human use. The application also discloses a recombinant expression vector, S. lividans host cell comprising said vector, the resulting enzyme preparation, formulations thereof, and clinical uses. Published April 23, 2026.

Novozyme Lactase Variants for Dairy, US20260109961A1

USPTO published patent application US20260109961A1, filed 2025-06-06 by Novozymes A/S (Denmark), covering novel lactase enzyme variants with modified galactose inhibition profiles. The variants are described as suitable for producing low-lactose or lactose-free dairy products. CPC classifications include C12N 9/2471 (amylases or glucoinosidases), A23C 9/1206 (lactose reduction), and C12N 15/52/63 (gene sequences and expression vectors). Inventors include Roland Alexander Pache, Anders Gunnar Sandstrom, Jan Kjoelhede Vester, Henrik Friis-Madsen, and Dorota Nissen. As a published application, no enforcement or compliance obligations arise from this document.

Adeno-Associated Virus Variant Patent Application

The USPTO published patent application US20260109956A1 on April 23, 2026, disclosing an adeno-associated virus 2 (AAV2) variant invented by Dong Woo Song and Hyekyung Oh. The application claims VP1 variants comprising amino acid sequences selected from SEQ ID NOS: 02 to 31. Filing date was October 28, 2025, under application number 19371743. The patent application is classified under CPC codes C12N 7/00 and C07K 14/005, placing it within the biotechnology and gene therapy vector arts.

CJ Cheiljedang L-Alanine Polynucleotide Patent Application

CJ Cheiljedang Corporation filed patent application US20260109957A1 on December 12, 2023, covering a novel polynucleotide and method for producing L-alanine, published April 23, 2026. The application discloses biotechnological methods for L-alanine production using the novel polynucleotide, with CPC classifications in C12N 9/1096 and related enzyme categories. Inventors include Ju-Yeon Kim, Min-Jung Kim, and Ji Hye Lee.

Mobile Network ANUP Patent by Zhang et al

USPTO published patent application US20260113157A1 titled 'Mobile Network User Plane with Access Network User Plane Function' filed by inventors Zhaohui Zhang, Constantine Dimitrios-Polychronopoulos, and Arda Akman on October 21, 2025 (Application No. 19364901). The application covers a method where an Access Network User Plane Function (ANUP) executes access network protocols to connect with user equipment, implements interfaces with data networks based on session data from a mobile core control plane function, and routes packets between the UE connection and data network interface. CPC classifications include H04L 5/0048, H04L 5/0064, H04W 8/04, and H04W 28/0263.

Dynamic Aperiodic SRS Slot Offset Indication for 5G Communication

Wei YANG, Alexandros MANOLAKOS, and Yu ZHANG filed Application No. 19425838 with the USPTO on December 18, 2025, for a method and system enabling dynamic aperiodic sounding reference signal (SRS) slot offset indication in 5G wireless communication networks. The published application (US20260113159A1) describes an indicator field utilized to signal slot offset to user equipment (UE), addressing timing synchronization in advanced wireless systems. If granted, the patent would provide the inventors with exclusive rights to the claimed aperiodic SRS indication technique.

CT Polyp Detection Using Dual CNN Architecture for Medical Imaging

USPTO published patent application US20260096796A1 for a CT polyp detection system employing dual convolutional neural network (CNN) architectures. The method receives CT scan image data, segments colon portions using a first CNN to identify candidate polyps, then validates candidates through multiplanar analysis using a second model to classify each as a polyp or non-polyp. The four named inventors are Aly Farag, Mohamed Yousuf, Samir Harb, and Asem Ali. The application was filed October 8, 2025 and published April 9, 2026.

Ultrasonic Diagnostic Device with Blood Flow Processing

USPTO published patent application US20260096809A1 for an ultrasonic diagnostic device with one or more processors configured to acquire measurement data including both tissue-derived and blood-flow-derived information, compute a deformation amount between a plurality of frames, and generate display image data by aligning and synthesizing feature points across those frames. The application was filed on December 10, 2025 under Application No. 19415098, naming Shoya Sasaki, Naoya Iizuka, Takeshi Sato, and Hiroki Takahashi as inventors.

Anumana Patent for Non-Invasive ECG and Echo Monitoring with Machine Learning

Anumana, Inc. filed patent application US20260096783A1 on April 9, 2026 (filed October 4, 2024 as Application No. 18907123) for an apparatus and method combining non-invasive ECG and echocardiogram data with machine learning to generate simulated invasive measurement data. The system fuses ECG and echo measurements and uses trained ML models to produce data equivalent to invasive cardiac measurements, transmitting results to remote devices. CPC classifications span cardiac monitoring (A61B 5/7267, A61B 5/256, A61B 5/346), medical imaging (G06T 15/005), and health informatics (G16H 50/20, G16H 50/70).

Systems and Methods for Automatic State Estimation of Current Imaging Exam Using User Actions on Console Screen

USPTO published patent application US20260096786A1 filed by seven inventors including SIVA CHAITANYA CHADUVULA, EKIN KOKER, OLGA STAROBINETS, RANJITH NAVEEN TELLIS, SANDEEP MADHUKAR DALAL, THOMAS ERIK AMTHOR, and YUECHEN QIAN. The application covers a system for automatically estimating the state of a medical imaging examination using video analysis and a state machine algorithm implemented in electronic processors, with results displayed on an electronic processing device. The filing date was September 19, 2023, with application number 19112526.

System to Monitor and Manage Patient Hydration via Plethysmograph Variability Index in Response to Passive Leg Raising

The USPTO published patent application US20260096773A1 on April 9, 2026, filed September 2, 2025, for a system using a processor to predict fluid responsiveness or unresponsiveness in patients based on plethysmograph variability parameters and limb-elevation fluid responsiveness parameters, then causing administration or termination of fluid delivery based on the combined prediction. The named inventors are Massi Joe E. Kiani, Bilal Muhsin, and Keith Ward Indorf. CPC classifications include A61B 5/4848 and G16H 20/17 (Health Informatics), with the application originating from US application number 19316927.

Bayesian Denoising for Retrospective PISA Detection in Analyte Traces

The USPTO published patent application US20260096780A1 for a Bayesian denoising method to detect pressure-induced sensor artifacts (PISA) in analyte traces. The method receives measured analyte data samples from a sensor, generates a reconstructed trace with confidence windows using a Bayesian algorithm, and compares the two to identify artifacts outside the confidence interval. Inventors include Andrea Facchinetti, Simone Del Favero, Giovanni Sparacino, Elena Idi, Eleonora Manzoni, and Nunzio Camerlingo. The application (No. 18908001) was filed October 7, 2024 and published April 9, 2026.

Insulin Dosage Patent Application by Stone, Mikhno, Turksoy, and Grossman

USPTO published patent application US20260096775A1 titled 'Open Loop Intelligent Dosing' on April 9, 2026. The application covers systems and techniques for generating personalized insulin dosage recommendations by building a physiological model from a patient's historical glucose and insulin data, estimating the impact of meal consumption on glucose levels, and outputting a personalized meal bolus insulin dose recommendation. The application was filed on September 16, 2025 under Application No. 19330568, with four named inventors: Michael P. Stone, Arthur Mikhno, Kamuran Turksoy, and Benyamin Grossman. This is a published patent application record; it has not yet been granted and creates no immediate compliance obligations.

Pain Detection Method Using Sensors in Personal Care Devices

USPTO published patent application US20260096772A1 titled "Pain Detection Method" on April 9, 2026, filed by six inventors including Amir Hussein Rmaile, Mark Thomas Johnson, and others. The application (No. 19114825, filed September 26, 2023) covers a method for objectively measuring user pain during personal care sessions using force and/or motion sensors integrated into personal care devices such as oral care devices. The sensor data patterns can infer pain levels, pain reaction events at specific points or locations, and increased sensitivity in certain body areas.

Ring-Type Wearable Device for Biometric Health Monitoring

USPTO published patent application US20260096777A1 on April 9, 2026, filed on May 8, 2025, by inventors Thomas Voigt and Swagatika Bhattacharya. The application covers a ring-type wearable device with multiple LEDs and photodetectors for biometric health monitoring. The published application does not grant any rights and represents an early-stage IP filing rather than an issued patent.

Nant Holdings IP Files Neoepitope Validation Patent, US20260110686A1

Nant Holdings IP, LLC has published patent application US20260110686A1, covering systems and methods for predicting MHC presentation of a neoepitope of a tumor or for predicting an immune response against an MHC presented neoepitope of a tumor. The application names inventors Kayvan Niazi and Nicholas J. Witchey, was filed on 2025-10-21 under Application No. 19364620, and was published on April 23, 2026. CPC classifications span immunology, peptides, and diagnostics (G01N, C07K, A61K series).

Glycoprotein Glycan Modification Method

Amgen Inc. has filed patent application US20260110013A1 covering a method for manipulating the fucosylated glycan content on recombinant proteins. The application, filed on October 22, 2025 (Application No. 19365891), was published on April 23, 2026. Inventors Daniel R. Leiske and Michael T. Trentalange are credited with the invention, which has implications for biopharmaceutical development and glycoprotein-based therapeutic manufacturing.

Methods for Standardizing Lectin Reagents, IgA1 Calibration Standards, and Quantitative Measurement of Galactose-Deficient IgA1

USPTO published patent application US20260110695A1 assigned to Reliant Glycosciences, LLC, covering methods for standardizing lectin reagents and measuring galactose-deficient IgA1 (Gd-IgA1) as a biomarker for IgA nephropathy. The application includes a lectin-based ELISA assay kit using standardized GalNAc-specific lectins such as biotinylated Helix pomatia agglutinin (HPA) or Helix aspersa agglutinin (HAA). Filed October 22, 2025, with inventors William Placzek, Thomasz Szul, Matthew Renfrow, Janusz Tucholski, and Jan Novak.

Mixture Of Interferon Alpha 2B With Modified Sequences Thereof

PharmaEssentia Corporation filed USPTO patent application US20260109750A1 for interferon-polymer conjugates to treat three rare blood disorders: idiopathic myelofibrosis, polycythaemia vera, and essential thrombocythaemia. The application was submitted on October 17, 2025, listing six inventors including Ko-Chung Lin and Shin-Jye Lee. CPC classifications include C07K 14/56, C12P 21/02, G01N 33/6824, and A61K 38/00.

US20260108577A1: Biotic Superparamagnetic Nanoparticles from Colchicum Ritchii

USPTO published patent application US20260108577A1 on April 23, 2026, disclosing a method for preparing biotic superparamagnetic nanoparticles using Colchicum ritchii plant extract combined with ferric chloride solution and sodium hydroxide solution. The application names VEERAMANI CHINNADURAI, KHALID S. AL-NUMAIR, and MOHAMMED A. ALSAIF as inventors, with a filing date of October 17, 2024, and application number 18918527. CPC classifications indicate pharmaceutical applications including weight management (A61P 3/04) and diabetes treatment (A61P 3/10).

BioDevas Laboratoires Patent for Aromatic Plant Extract Flea Treatment Composition

BioDevas Laboratoires has been granted USPTO Application US20260108576A1 for a composition against ectoparasites, specifically fleas affecting domestic mammals. The composition comprises a mixture of extracts from aromatic plants, including lemon balm, thyme, rosemary, wormwood, and lemongrass. The application was filed on December 22, 2025, under Application No. 19428445, with inventors François BLUA and Jean Louis BLUA. The patent covers veterinary and pharmaceutical compositions incorporating the extract mixture, along with animal food products containing the composition and methods for preparing and administering the composition for flea prevention or treatment.

Method for Preparing Biotic Superparamagnetic Nanoparticles Derived from Colchicum Ritchii

USPTO has published patent application US20260108578A1 for a method of preparing biotic superparamagnetic nanoparticles using Colchicum ritchii plant extract. The application, filed on January 17, 2025 by inventors Veeramoni Chinnadurai, Khalid A. Al-Numair, and Mohammed A. Alsaif, describes combining the plant extract with ferric chloride solution followed by sodium hydroxide to form superparamagnetic nanoparticles. The invention is classified under CPC codes A61K 36/88, A61K 9/5115, A61K 9/5192, A61K 47/02, A61P 3/04, and A61P 3/10, indicating applications in pharmaceutical preparations for metabolic disorders.

Nrf2 Activation Compositions, Treat Inflammation, Oxidative Stress

USPTO published patent application US20260108575A1 on April 23, 2026, filed by Brooks Michael Hybertson and Joe Milton McCord under Application No. 19370063. The application covers compositions containing phytochemicals that activate Nrf2 pathways for preventing or treating health conditions associated with inflammation or oxidative stress. The filing date was October 27, 2025, and CPC classifications include A61K 36/53, A61K 31/352, A61K 36/906, and A61K 45/06.

Calluna Vulgaris for Urinary Tract Infection Treatment

USPTO published patent application US20260108573A1 by inventor Heather Florio on April 23, 2026, covering methods and compositions of Calluna vulgaris for the prevention and treatment of urinary tract infections. The application (No. 19322118) was filed on September 8, 2025 and classifies under CPC codes A61K 36/45, A61K 9/14, and A61P 13/02.

US20260108574A1 Herbal Composition for Metabolic Disorders

The USPTO has published patent application US20260108574A1, filed October 16, 2025 by M/S Natural and Essential Oils Private Limited, disclosing a herbal composition for treating metabolic disorders in mammals including central obesity, high blood pressure, high blood sugar, stress-induced fatigue, and type 2 diabetes. The composition comprises extracts of Dolichos lablab, Achyranthes aspera, and Cinnamomum zeylanicum or Cinnamomum cassia, standardized to contain proanthocyanidins, saponins, polyphenols, and tannins. The application describes methods of preparation and therapeutic effects including enhanced adiponectin and HDL levels.

Ophthalmic Formulations, Pelthos Therapeutics, Eye Pain

Pelthos Therapeutics Inc. filed US Patent Application US20260108500A1 on October 22, 2025, covering ophthalmic formulations comprising 2-{[3-(5-chloro-2-{2-chloro-5-fluoro-4-[(1,3-thiazol-4-yl)sulfamoyl]phenoxy}phenyl)propyl]amino}acetamide or a pharmaceutically acceptable salt thereof. The application names four inventors: Eric D. Lang, Simon Paul Chandler, Deshou Jiang, and Richard Malamut. The formulations are directed to treatment of various eye conditions including pain.